China’s NMPA Drafts Market Exclusivity Rules for Rare Disease and Pediatric Drugs
China’s National Medical Products Administration (NMPA) has drafted measures to grant market exclusivity to qualifying rare disease and pediatric drugs. During the exclusivity period, NMPA would not approve competing products of the same variety. A rare disease drug would qualify if it... Read More